Sg3 Management, LLC Neurocrine Biosciences Inc Call Options Transaction History

Sg3 Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $970,112 - $1.28 Million	-12,800 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $57,960 - $75,848	800 Added 6.67%	12,800 $1.2 Million
Q4 2021 Feb 15, 2022	BUY	$79.65 - $106.22 $955,800 - $1.27 Million	12,000 New	12,000 $1.02 Million
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $1.72 Million - $1.98 Million	-20,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $1.79 Million - $2.05 Million	-20,000 Reduced 50.0%	20,000 $1.95 Million
Q1 2021 May 17, 2021	BUY	$87.57 - $119.4 $2.19 Million - $2.99 Million	25,000 Added 166.67%	40,000 $3.89 Million
Q3 2020 Nov 13, 2020	BUY	$96.16 - $135.15 $1.44 Million - $2.03 Million	15,000 New	15,000 $1.44 Million

627

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.2B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.